Scholarlink

Purpose <p>Acute hypoxemic respiratory failure (ARF) is a major challenge in immunocompromised patients, often complicated by severe respiratory distress and organ dysfunction. High-flow nasal oxygen (HFNO) therapy is the standard of care, but data on its effectiveness and outcomes are limited. This study evaluated the outcomes of HFNO in this population, predictors of invasive mechanical ventilation (IMV), and factors associated with 28-day mortality.</p> Methods <p>We analyzed data from a multicenter cohort of 986 immunocompromised patients with ARF treated with HFNO. Predictive factors for IMV and mortality were assessed using multivariable survival models, and the predictive value of the respiratory rate‑oxygenation (ROX) index for IMV was evaluated.</p> Results <p>Patients had a median age of 63&#xa0;years [IQR 54–70], and 66% were male. Primary causes of immunosuppression included hematologic malignancies (55%), solid tumors (30%), and solid-organ transplantation (10%). Bacterial pneumonia (40%) and opportunistic infections (15%) were the most common ARF etiologies. IMV was required in 46% of patients. Day 28 mortality was 33%, with better outcomes for solid-organ transplant recipients compared to hematologic malignancy or solid tumor (70% vs. 48% vs. 51% mortality, respectively). Predictors of IMV included a lower ROX index, higher respiratory rates, and lower PaO<sub>2</sub>/FiO<sub>2</sub> ratios. Mortality was highest among patients requiring IMV, particularly those with myeloid malignancies or viral pneumonia.</p> Conclusions <p>HFNO outcomes in immunocompromised patients with ARF vary widely, influenced by immunosuppression type, ARF etiology, and clinical factors. Optimizing treatment and identifying high-risk patients could improve outcomes. Prospective studies are needed to enhance HFNO strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes in immunocompromised patients with acute hypoxemic respiratory failure treated by high-flow nasal oxygen

  • 期刊论文

  • 发表日期：

    2025年4月22日

查看全文
  • Elie Azoulay,
  • Mélanie Métais,
  • Virginie Lemiale,
  • Djamel Mokart,
  • Anne-Sophie Moreau,
  • Emmanuel Canet,
  • Achille Kouatchet,
  • Laurent Argaud,
  • Peter Pickkers,
  • Philippe R. Bauer,
  • Andry van de Louw,
  • Ignacio Martin-Loeches,
  • Sangeeta Mehta,
  • Christophe Girault,
  • Florent Wallet,
  • Frédéric Pène,
  • Alexandre Demoule,
  • Alexis Maillard

摘要

Purpose

Acute hypoxemic respiratory failure (ARF) is a major challenge in immunocompromised patients, often complicated by severe respiratory distress and organ dysfunction. High-flow nasal oxygen (HFNO) therapy is the standard of care, but data on its effectiveness and outcomes are limited. This study evaluated the outcomes of HFNO in this population, predictors of invasive mechanical ventilation (IMV), and factors associated with 28-day mortality.

Methods

We analyzed data from a multicenter cohort of 986 immunocompromised patients with ARF treated with HFNO. Predictive factors for IMV and mortality were assessed using multivariable survival models, and the predictive value of the respiratory rate‑oxygenation (ROX) index for IMV was evaluated.

Results

Patients had a median age of 63 years [IQR 54–70], and 66% were male. Primary causes of immunosuppression included hematologic malignancies (55%), solid tumors (30%), and solid-organ transplantation (10%). Bacterial pneumonia (40%) and opportunistic infections (15%) were the most common ARF etiologies. IMV was required in 46% of patients. Day 28 mortality was 33%, with better outcomes for solid-organ transplant recipients compared to hematologic malignancy or solid tumor (70% vs. 48% vs. 51% mortality, respectively). Predictors of IMV included a lower ROX index, higher respiratory rates, and lower PaO2/FiO2 ratios. Mortality was highest among patients requiring IMV, particularly those with myeloid malignancies or viral pneumonia.

Conclusions

HFNO outcomes in immunocompromised patients with ARF vary widely, influenced by immunosuppression type, ARF etiology, and clinical factors. Optimizing treatment and identifying high-risk patients could improve outcomes. Prospective studies are needed to enhance HFNO strategies.